Trial · NCT05273749
Adverse events22
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 22
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypoaesthesia oral | Gastrointestinal disorders | TNX-102 SL Tablet, 5.6 mg | 55 | 231 | |
| other | Hypoaesthesia oral | Gastrointestinal disorders | Placebo SL Tablet | 1 | 226 | |
| other | Paraesthesia oral | Gastrointestinal disorders | TNX-102 SL Tablet, 5.6 mg | 16 | 231 | |
| other | Paraesthesia oral | Gastrointestinal disorders | Placebo SL Tablet | 2 | 226 | |
| other | Tongue discomfort | Gastrointestinal disorders | TNX-102 SL Tablet, 5.6 mg | 16 | 231 | |
| other | Tongue discomfort | Gastrointestinal disorders | Placebo SL Tablet | 0 | 226 | |
| other | Product taste abnormal | Product Issues | TNX-102 SL Tablet, 5.6 mg | 27 | 231 | |
| other | Product taste abnormal | Product Issues | Placebo SL Tablet | 2 | 226 | |
| serious | Pancreatitis acute | Gastrointestinal disorders | TNX-102 SL Tablet, 5.6 mg | 1 | 231 | |
| serious | Pancreatitis acute | Gastrointestinal disorders | Placebo SL Tablet | 0 | 226 | |
| serious | Renal Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | TNX-102 SL Tablet, 5.6 mg | 1 | 231 | |
| serious | Renal Cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Placebo SL Tablet | 0 | 226 | |
| serious | Angina pectoris | Cardiac disorders | TNX-102 SL Tablet, 5.6 mg | 0 | 231 | |
| serious | Angina pectoris | Cardiac disorders | Placebo SL Tablet | 1 | 226 | |
| serious | Pneumonia | Infections and infestations | TNX-102 SL Tablet, 5.6 mg | 0 | 231 | |
| serious | Pneumonia | Infections and infestations | Placebo SL Tablet | 1 | 226 | |
| serious | Muscular weakness | Musculoskeletal and connective tissue disorders | TNX-102 SL Tablet, 5.6 mg | 0 | 231 | |
| serious | Muscular weakness | Musculoskeletal and connective tissue disorders | Placebo SL Tablet | 1 | 226 | |
| serious | Hypertension | Vascular disorders | TNX-102 SL Tablet, 5.6 mg | 0 | 231 | |
| serious | Hypertension | Vascular disorders | Placebo SL Tablet | 1 | 226 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05273749/events